WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

PHARMACOECONOMICS EVALUATION OF TELMISARTAN AS MONOTHERAPY COMPARED WITH TELMISARTAN PLUS HYDROCHLOROTHIAZIDE AS COMBINATION THERAPY IN HYPERTENSIVE PATIENTS

Md Nematullah*, Rizwana Parveen, Rajveer Singh, Ranjeet Kumar

 

ABSTRACT

Background: Hypertension is silent killer it is not a disease it is a disorder. The Pharmacoeconomics study focuses on cost and benefit of the therapy. Monotherapy compared with the combination therapy. Aim: The aim of study to evaluate cost-effectiveness of telmisartan as monotherapy compared with telmisartan plus hydrochlorothiazide as combination therapy in hypertensive patients in tertiary care teaching hospital, Jaipur. Methods: A prospective observational study of six month conducted on the hypertension patients at general male medicine ward and female medicine ward with n=80 patients. A systemic protocol followed to obtained permission Institutional Ethical Committee (IEC) by submitting a proper protocol, data collection form, patient information and patient consent form. Result: Out of 80 patients it was found that in the study the cost of telmisartan was less and more cost-effectiveness as compare to telmisartan plus HCTZ. Conclusion: Telmisartan is a cost-saving therapy compared with Telmisartan plus HCTZ in HTN patients.

Keywords: Telmisartan, Telmisartan plus hydrochlorothiazide, Hypertension.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More